Protect Our Communities! Share Your Concerns With Gilead About Their New Prevention Trial
November 16, 2016
Gilead has recently launched a prevention study testing the safety and efficacy of F/TAF (Descovy) as PrEP. This drug is already being used for treatment for people living with HIV, and the drug maker wants to see if it works as prevention for HIV-negative people.
We are all for research into new methods of HIV prevention, but community advocates from North America and across Europe, including HIV PJA, are deeply concerned about Gilead's failure to follow internationally agreed upon guidelines known as Good Participatory Practice (GPP).
Why Our Concern?
Gilead has never conducted this kind of large HIV prevention trial and, so far, has shown a lack of understanding around the critical role of community engagement. HIV organizations in the United States, Canada and several countries in Europe, where the trial is already underway or planned to start, are asking Gilead to temporarily halt the trial until all of the necessary protections are put in place.
These include following the GPP guidelines closely and ensuring that people at increased risk of HIV are connected to services to discuss their risk, to learn important information about PrEP and decide what is best for them as individuals.
Check out this fact sheet to learn more about the trial.
This article was provided by HIV Prevention Justice Alliance. Visit HIV Prevention Justice Alliance's website to find out more about their activities and publications.
Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)
The content on this page is free of advertiser influence and was produced by our editorial team. See our advertising policy.